pyrazines has been researched along with Orthomyxoviridae Infections in 14 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (7.14) | 29.6817 |
2010's | 10 (71.43) | 24.3611 |
2020's | 3 (21.43) | 2.80 |
Authors | Studies |
---|---|
Kawaoka, Y; Kiso, M; Yamayoshi, S | 1 |
Abed, Y; Baz, M; Boivin, G; Checkmahomed, L; Padey, B; Pizzorno, A; Rosa-Calatrava, M; Terrier, O | 1 |
Akinbami, O; Barclay, WS; Frise, R; Galiano, M; Gallego Cortés, A; Goldhill, DH; Lackenby, A; Miah, S; Shelley, J; Yan, A; Zambon, M; Zhou, J | 1 |
Bank, C; Bolon, DN; Finberg, RW; Jensen, JD; Kowalik, TF; Liu, P; Matuszewski, S; Ormond, L; Renzette, N; Wang, JP; Zeldovich, K | 1 |
Hasegawa, H; Ito, M; Kawaoka, Y; Kiso, M; Lopes, TJS; Nakajima, N; Neumann, G; Yamashita, M; Yamayoshi, S | 1 |
Baz, M; Boivin, G; Carbonneau, J; Cavanagh, MH; Rhéaume, C | 1 |
Govorkova, EA; Marathe, BM; Pascua, PNQ; Vogel, P; Webby, RJ | 1 |
Bailey, T; Boon, ACM; Bricker, TL; Diamond, MS; Gounder, AP; Jagger, BW; Janowski, AB; Kwon, JH; Shafiuddin, M; Wang, D; Williams, GD; Zhao, G | 1 |
Bae, JY; Baek, LJ; Cheong, HJ; Heo, J; Hwang, MW; Jang, SI; Kim, D; Kim, H; Kim, JI; Lee, I; Lee, S; Park, MS; Park, S; Song, JW; Song, KJ | 1 |
Garcia-Alcalde, F; Govorkova, EA; Marathe, BM; Najera, I; Vogel, P; Webby, RJ; Webster, RG; Wong, SS | 1 |
Bailey, KW; Furuta, Y; Hurst, BL; Morrey, JD; Smee, DF; Tarbet, EB; Wong, MH | 1 |
Lee, SM; Yen, HL | 1 |
Armstrong, J; Baranovich, T; Govorkova, EA; Marjuki, H; Webby, RJ; Webster, RG; Wong, SS | 1 |
Egawa, H; Fukuda, Y; Furuta, Y; Kamiyama, T; Kozaki, K; Kuno, M; Minami, S; Nomura, N; Shiraki, K; Takahashi, K | 1 |
1 review(s) available for pyrazines and Orthomyxoviridae Infections
Article | Year |
---|---|
Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection.
Topics: Amides; Animals; Antibodies, Viral; Antiviral Agents; Cross Reactions; Host-Pathogen Interactions; Humans; Immunomodulation; Influenza A virus; Orthomyxoviridae Infections; Pyrazines; Receptors, Cell Surface; Viral Matrix Proteins; Virus Attachment; Virus Internalization; Virus Replication | 2012 |
13 other study(ies) available for pyrazines and Orthomyxoviridae Infections
Article | Year |
---|---|
Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice.
Topics: Amides; Animals; Antibodies, Monoclonal; Antiviral Agents; Drug Therapy, Combination; Female; Hemagglutinins, Viral; Influenza A Virus, H1N1 Subtype; Mice; Mice, Nude; Orthomyxoviridae Infections; Pyrazines | 2020 |
In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cell Line; Dibenzothiepins; Dogs; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Guanidines; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Morpholines; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Pyridones; Ribavirin; Triazines; Viral Proteins; Virus Replication; Zanamivir | 2020 |
Favipiravir-resistant influenza A virus shows potential for transmission.
Topics: Amides; Animals; Antiviral Agents; Drug Resistance, Viral; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Orthomyxoviridae Infections; Pyrazines | 2021 |
The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution.
Topics: Amides; Animals; Antiviral Agents; Biological Evolution; Cell Line; Dogs; Genetics, Population; Influenza A virus; Mutation Rate; Orthomyxoviridae Infections; Oseltamivir; Pyrazines | 2017 |
Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.
Topics: Amides; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Nude; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Pyrazines; Sialic Acids; Zanamivir | 2018 |
Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
Topics: Amides; Animals; Antiviral Agents; Cytokines; Disease Models, Animal; Drug Resistance, Viral; Drug Therapy, Combination; Female; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Mice; Orthomyxoviridae Infections; Oseltamivir; Pyrazines | 2018 |
Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.
Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Disease Models, Animal; Dogs; Epithelial Cells; Female; Immunocompromised Host; Influenza B virus; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Mice, SCID; Orthomyxoviridae Infections; Pyrazines; Viral Load; Virus Replication | 2019 |
Therapeutic efficacy of favipiravir against Bourbon virus in mice.
Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Disease Models, Animal; Humans; Mice; Mice, Knockout; Orthomyxoviridae Infections; Pyrazines; Receptor, Interferon alpha-beta; Thogotovirus; Vero Cells; Viral Tropism | 2019 |
Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Body Weight; Cyclopentanes; Dogs; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred DBA; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate | 2014 |
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice.
Topics: Amides; Animals; Dogs; Drug Therapy, Combination; Female; Influenza A Virus, H5N1 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Orthomyxoviridae Infections; Oseltamivir; Pyrazines | 2016 |
Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.
Topics: Amides; Animals; Antiviral Agents; Cell Line; Drug Combinations; Drug Interactions; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrazines | 2010 |
T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.
Topics: Amides; Analysis of Variance; Animals; Antiviral Agents; Dogs; Drug Discovery; In Vitro Techniques; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Mutagenesis; Orthomyxoviridae Infections; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.
Topics: Acetamides; Amides; Animals; Antiviral Agents; Drug Evaluation, Preclinical; Influenza A virus; Mice; Orthomyxoviridae Infections; Oseltamivir; Pyrazines; Survival Rate; Time Factors | 2003 |